Business Context and Reporting Period
This Form 8-K was filed by Processa Pharmaceuticals, Inc. on March 22, 2023. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock's closing bid price, which had been below $1.00 per share for the previous 30 consecutive business days.
Material Changes
The material event reported is the receipt of a Notice of Delisting or Failure to Satisfy a Continued Listing Rule. Specifically, the company failed to meet Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market.
Outlook, Risks, and Contingencies
- Compliance Period: The company has been granted an initial 180-day compliance period, ending on September 18, 2023, to regain compliance.
- Regaining Compliance: Compliance can be achieved if the bid price closes at $1.00 or more for a minimum of 10 consecutive business days before the compliance date.
- Delisting Risk: If the company fails to regain compliance by the deadline, it may qualify for a second 180-day period. Failure to comply during the second period will result in a delisting notice.
- Appeal Process: The company may appeal a delisting determination to the Nasdaq Hearings Panel, though there is no assurance of success.
- Current Status: The notice has no immediate effect on trading; the stock continues to trade under the symbol "PCSA."
Investor Verification Checklist
- Verify the current closing bid price of PCSA to assess proximity to the $1.00 threshold.
- Monitor the company's stock performance over the next 10 consecutive business days to determine if the initial compliance requirement is met.
- Review future filings for updates on the compliance status before the September 18, 2023 deadline.
- Check for any announcements regarding a reverse stock split or other corporate actions intended to address the bid price deficiency.